Abstract
Novel estrogen-conjugated pyridine-containing Gd(III) and Eu(III) contrast agents (EPTA-Gd/Eu) were designed and effectively synthesized. Convenient to administration and MRI experiments, both EPTA-Gd and EPTA-Eu are soluble in water. The EPTA-Gd selectively binds with a micromolar affinity to the estrogen receptor and induces proliferation of human breast cancer cells. The EPTA-Gd is not lethal and does not cause any adverse effects when administrated intravenously. It enhances T1 and T2 nuclear relaxation rates of water and serves as a selective contrast agent for localizing the estrogen receptor by MRI.
Original language | English |
---|---|
Pages (from-to) | 1361-1365 |
Number of pages | 5 |
Journal | Bioconjugate Chemistry |
Volume | 18 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2007 |
All Science Journal Classification (ASJC) codes
- Bioengineering
- Biotechnology
- Biomedical Engineering
- Pharmacology
- Pharmaceutical Science
- Organic Chemistry